ClinicalTrials.gg
Active, not recruitingNCT05181475Updated Nov 15, 2024

Long-term Efficacy and Safety Study of GV-971

A Phase 4 interventional study of Sodium Oligomannate Capsules (GV-971) in Alzheimer Disease, sponsored by Green Valley (Shanghai) Pharmaceuticals Co., Ltd.. Active, not recruiting at 40 sites in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-11-15.

Sponsored by Green Valley (Shanghai) Pharmaceuticals Co., Ltd. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
800
Allocation
Not applicable
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 260 studies in Alzheimer Disease with a site in China — 150 open to participants now, 162 under way, 21 of them phase 3. Alzheimer Disease · China.

Enrollment
22nd of 176
800 · median 100
Started
2021
with 15 others
Phase 4
11 of 260
4 open now
Primary completion
2025-01
later than 10 of 161 live
Registered
83rd of 260
by date

Among the 260 studies in Alzheimer Disease with a site in China, this one is the 22nd largest by enrollment of the 176 interventional ones that give a count, is one of 16 that started in 2021, is one of 11 in phase 4, reaches primary completion later than 10 of the 161 other live ones, and was the 83rd registered.

Alzheimer Disease

3,968 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

150 of the 260 studies in Alzheimer Disease with a site in China are open now. Recruiting first, the newest first:

145 more — sign in →

All 150 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Alzheimer Disease with a site in China, or all of them as a file.
02

Study summary

Sodium Oligomannate Capsules (GV-971) has been approved for treatment of mild to moderate Alzheimer's disease and improving the cognitive function of patients. This study plans to observe, in the clinical patients, the long-term efficacy and safety of GV-971, as well as the changes in blood and gut microbiota biomarkers after treatment, to validate the mechanism of action of GV-971, in order to better guide the rational use of drug in clinical practice.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 50 to 85 years (inclusive), with no restriction on gender;
  2. Patients who met criteria for "probable AD" by National Institute on Aging and Alzheimer's Association (NIA-AA) diagnostic criteria;
  3. Patients with mild to moderate AD as characterized by (MMSE) scores between 11 and 26, inclusive;
  4. Patients who have received at least primary education and have capacity to complete the measurement of cognition and other tests as specified in the protocol;
  5. Patients receiving GV-971 treatment prescribed by clinicians;
  6. Sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have received GV-971 treatment within 6 months prior to screening;
  2. Patients who may be allergic to Sodium Oligomannate Capsules as judged by the investigator;
  3. Female participants who are pregnant or lactating;
  4. Patients who cannot cooperate to complete the follow-up inquiries;
  5. Any other diseases or conditions that are inappropriate to participate in this clinical trial in the opinion of the investigator.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
800 participants (actual)

Study arms

  • Experimental
    Sodium Oligomannate Capsules (GV-971)

    The recommended dose regimen for subjects: GV-971 450 mg (3 capsules) per dose, bid, po. in morning and evening

    Drug: Sodium Oligomannate Capsules (GV-971)

Interventions

  • Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.

06

What researchers measure

Primary outcomes

  1. Change from baseline in the ADAS-cog/11 score

    Change from baseline in Alzheimer's Disease Assessments Scale - cognitive (ADAS-cog/11) scale total score. The total score of ADAS-cog/11 is 0-70, with higher scores mean a worse outcome.

    Time frame: Baseline, 48 weeks

Secondary outcomes

  1. Change from baseline in ADAS-Cog/11 score

    Change from baseline in Alzheimer's Disease Assessments Scale - cognitive (ADAS-cog/11) scale total score. The total score of ADAS-cog/11 is 0-70, with higher scores mean a worse outcome.

    Time frame: Baseline, 96 weeks

  2. Change from baseline in MMSE score

    Change from baseline in Mini Mental State Examination (MMSE) score. The total score of MMSE is 0-30, with higher scores mean a better outcome.

    Time frame: Baseline, 48 weeks, 96 weeks

  3. Change from baseline in ADCS-ADL score

    Change from baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living; 23-item Scale (ACDS-ADL23) score. The total score of ADCS-ADL23 is 0-78, with higher scores mean a better outcome.

    Time frame: Baseline, 48 weeks, 96 weeks

  4. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    The incidence of adverse events and adverse reactions of vital signs, laboratory tests, electrocardiogram, and early withdrawal from the study in patients treated with GV-971.

    Time frame: 48 weeks, 96 weeks

07

Study locations

40 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Jan 2025, 37 months after the start.

Of 41 phase 4 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2021
First posted
Jan 6, 2022
StartActual
Dec 7, 2021
Primary completionEst.
Jan 2025
CompletionEst.
Jun 2025
Last update
Nov 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05181475
Lead sponsor
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Jan 6, 2022
Start date
Dec 7, 2021
Primary completion
Jan 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Nov 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GV-971

Start the discussion